Techniques for Determining Protein Binding in Drug Discovery and Development

ADME-Enabling Technologies in Drug Design and Development

Volumn , Issue , 2012, Pages 177-187

  Lloyd, Tom ^a  

^a Worldwide Clinical Trials Drug Development Solutions Bioanalytical Sciences   (United States)

Author keywords

Capillary electrophoretic methods, in drug protein binding; Drug delivery to brain and automation, Autogizer , Tomtec , Hamden, CT; Equilibrium dialysis, gold standard determining drug protein binding; Protein binding in drug discovery and development, and techniques; Ultracentrifugation, ultrafiltration, microdialysis, spectroscopy

Indexed keywords

EID: 84885376224     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118180778.ch12     Document Type: Chapter

References (71)

1. Kwong TC (1985) Free drug measurements: Methodology and clinical significance. Clin Chim Acta 151: 193.
2. Levy RH, Moreland TA (1984) Rational for monitoring free drug level. Clin Pharmacokinet 9 (Suppl 1): 1.
3. Svensson CK, Woodruff MN, Baxter JG, Lalka D (1986) Free drug concentration monitoring in clinical practice: Rationale and current status. Clin Pharmacokinet 11: 450.
4. Tang Y, Zhu H, Zhang Y, Huang C (2006) Determination of human plasma protein binding of baicalin by ultrafiltration and high-performance liquid chromatography. Biomed Chromatogr 20: 1116-1119.
5. Greenblatt DJ, Sellers EM, Koch-Weser J (1982) Importance of protein binding for the interpretation of serum and plasma drug concentrations. J Clin Pharmacol 22: 259-263.
6. Herve F, Urien S, Albengres E, Duche J (1994) Drug binding in plasma. Clin Pharmacokinet 25 (1): 44-58.
7. Schuhmacher J, Buhner K, Witt-Laido A (2000) Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 89: 1008-1021.
8. Swift CG, Ewin JM, Clark P, Stevenson IH (1985) Responsiveness to oral diazepam in the elderly: Relationship to total and free plasma concentrations. Br J Clin Pharmacol 20 (2): 111-118.
9. Wilkinson GR (1983) Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 14: 427-465.
10. Tozer TN (1981) Concepts basic to pharmacokinetics. Pharmacol Ther 12: 109-131.
11. Trainor GL (2007) The importance of plasma protein binding in drug discovery. Expert Opin Drug Discov 2 (1): 51-64.
12. Wan H, Holmen AG (2007) High throughput screening of physiochemical properties and in vitro ADME profiling in drug discovery. Comb Chem High Throughput Screen 50: 4606-4615.
13. Jusko WJ, Gretch M (1976) Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev 5 (1): 42-139.
14. Wallace WM, Verbeek RK (1987) Plasma protein binding of drugs in the elderly. Clin Pharmacokinet 12: 40-72.
15. Zini R, Riant P, Barre J, Tillement JP (1990) Disease-induced variations in plasma protein levels. Clin Pharmacokinet 19 (2): 147-159.
16. Routledge PA, Barchowsky A, Bjornsson A, Kitchell BB, Shand DG (1980) Lidocaine plasma protein binding. Clin Pharmacol Ther 26 (3): 336-347.
17. Kariv I, Cao H, Oldenburg KR (2001) Development of a high throughput equilibrium dialysis method. J Pharm Sci 90: 580-587.
18. Oravcova J, Bohs B, Lindner W (1996) Drug-protein binding studies new trends in analytical and experimental methodology. J Chromatogr B 677: 1-28.
19. Singh SS, Mehta J (2006) Measurement of drug-protein binding by immobilized human serum albumin-HPLC and comparison with ultrafiltration. J Chromatogr B 834: 108-116.
20. Naranjo CA, Sellers EM Drug-Protein Binding. New York, NY: Praeger, 1986: 233-251.
21. Gilman AG, Goodman LS, Rall TW, Murad F, eds. Goodman and Gilman' s The Pharmacological Basis of Therapeutics, 7th ed., New York, NY: MacMillan, 1985: 12, 54, 889, 1664-1735.
22. Pacifici GM, Viani A (1992) Methods of determining plasma and tissue binding of drugs. Clin Pharmacokinet 23: 449-468.
23. Sebille B (1990) Methods of drug protein binding determinations. Fundam Clin Pharmacol 4 (Suppl 2): 151-161.
24. Kristensen CB, Gram LF (1982) Equilibrium dialysis for determination of protein binding of imipramine-evaluation of a method. Acta Pharmacol Toxicol (Copenh) 50: 129-135.
25. Dayton PG, Stiller RL, Cook DR, Perel JM (1983) The binding of ketamine to plasma proteins: Emphasis on human plasma. Eur J Clin Pharmacol 24: 825-830.
26. Ponganis KV, Stanski DR (1985) Factors affecting the measurement of lidocaine protein binding by equilibrium dialysis in human serum. J Pharm Sci 74 (1): 57-60.
27. Musteata FM, Pawliszyn J, Qian MG, Wu JT, Miwa GT (2006) Determination of drug plasma protein binding by solid phase microextraction. J Pharm Sci 95(8): 1712-1722.
28. Fura A, Harper TW, Zhang H, Fung L, Shyu WC (2003) Shift in pH of biological fluids during storage and processing: Effect on bioanalysis. J Pharm Biomed Anal 32: 513-522.
29. Lloyd TL, Ghupur A, Chun A, Sears S, Liu Z (2009) Alternative Automated Methods for Free Fraction Determination in Tissue and Plasma. Applied Pharmaceutical Analysis Conference on September 16, 2009, in Boston, MA.
30. Waters NJ, Jones R, Williams G, Sohal B (2007) Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci 97 (10): 4586-4595.
31. Allen MC, Shah TS, Day WW (1998) Rapid determination of oral pharmacokinetics and plasma free fraction using cocktail approaches: Methods and applications. Pharm Res 15 (1): 93-97.
32. Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, Greenblatt DJ (2002) Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30 (12): 1441-1445.
33. Taylor S, Harker A (2005) Modification of the ultrafiltration technique to overcome solubility and non-specific binding challenges associated with the measurement of plasma protein binding of corticosteroids. J Pharm Biomed Anal 41: 299-303.
34. Fung EN, Chen YH, Lau YY (2003) Semi-automatic high-throughput determination of plasma protein binding using a 96-well plate filtrate assembly and fast liquid chromatography-tandem mass spectrometry. J Chromatogr B 795: 187-194.
35. Wan H, Rehngren M, Giordanetto F, Bergstrom F, Tunek A (2007) High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50: 4606-4615.
36. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
37. Banker MJ, Clark TH, Williams JA (2002) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92: 967-974.
38. Huang J (1983) Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis. J Pharm Sci 72: 1358-1359.
39. Lima J, MacKichan JJ, Libertin N, Sabino J (1983) Influence of volume shifts on drug binding during equilibrium dialysis: Correction and attenuation. J Pharmacokinet Biopharm 11: 483-498.
40. Boudinot FD, Jusko WJ (1984) Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 73: 774-780.
41. Khor SP, Wu HJ, Boxenbaum H (1985) Simultaneous correction for volume shifts and leakage in equilibrium dialysis protein binding experiments. Int J Pharm 23: 109-113.
42. Mapleson WW (1987) Computation of the effect of Donnan equilibrium on pH in equilibrium dialysis. J Pharmacol Methods 17: 231-242.
43. Fisher WR, Hammond MG, Warmke GL (1972) Measurements of the molecular weight variability of plasma low density lipoproteins among normals and subjects with hyper-b-lipoproteinemia. Biochemistry 11: 519-525.
44. Barre J, Chamouard JM, Houin G, Tillement JP (1985) Equilibrium dialysis, ultrafiltration and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 31: 60-64.
45. Bombardt PA, Brewer JE, Johnson MG (1994) Protein binding of tirilazad (U-74006) in human, Sprague-Dawley rat, beagle dog and cynomolgus monkey serum. J Pharmacol Exp Ther 269: 145-150.
46. Zini R Methods in drug protein binding analysis. In Human Pharmacology. The Basis of Clinical Pharmacology, Kuemmerle H, Shibuya T, Tillement JP eds. Oxford, UK: Elsevier Science, 1991: 235-282.
47. Kurz H, Trunk H, Weitz B (1977) Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration. Arzneimittelforschung 27: 1373-1380.
48. Legg B, Rowland M (1987) Cyclosporin: Measurement of fraction unbound in plasma. J Pharm Pharmacol 39: 599-603.
49. Nakai D, Kumamoto K, Sakikawa C, Kosaka T, Tokui T (2003) Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci 93 (4): 847-854.
50. Adams W, Ghupur A, Lloyd TL (2009) Cross-validation of a reduced volume, semi-automated ultracentrifugation process for assessing protein binding in plasma and microsomes to improve efficiency and capacity. Eastern Analytical Symposium, Somerset, NJ, November 18, 2009.
51. Heinze A, Holzgrabe U (2006) Determination of the extent of protein binding of antibiotics by means of an automated continuous ultrafiltration method. Int J Pharm 311: 108-112.
52. Johansen K, Krogh M, Andresen AT, Christophersen AS, Lehne G, Rasmussen KE (2005) Automated analysis of free and total concentrations of three antiepileptic drugs in plasma with on-line dialysis and high-performance liquid chromatography. J Chromatogr B 669 (2): 281-288.
53. Mandla R, Line PD, Midtvedt K, Bergan S (2003) Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. Ther Drug Monit 25 (3): 407-414.
54. Chaurasia CS, et al. (2007) AAPS-FDA workshop white paper: Microdialysis principles, application, and regulatory perspectives report from the joint AAPS-FDA workshop, November 4-5, 2005, Nashville, TN. AAPS J 9 (1): 48-59.
55. Ungerstedt U (1991) Microdialysis-principles and applications for studies in animals and man. J Intern Med 230: 365-373.
56. Smith AD, Justice JB (1994) The effect of inhibition of synthesis, release, metabolism and uptake on the microdialysis extraction fraction of dopamine. J Neurosci 54: 75-82.
57. Vuignier K, Schappler J, Veuthey JL, Carrupt PA, Martel S (2010) Drug-protein binding: A critical review of analytical tools. Anal Bioanal Chem 398: 53-66.
58. Cimitan S, Lindgren MT, Bertucci C, Danielson UH (2005) Early absorption and distribution analysis of antitumor and anti-AIDS drugs: Lipid membrane and plasma protein interactions. J Med Chem 48 (10): 3536-3546.
59. Rich RL, Myszka DG (2004) Why you should be using more SPR biosensor technology. Drug Discov Today Technol 1: 301-308.
60. Lazaro E, Lowe PJ, Briand X, Faller B (2008) New approach to measure protein binding based on a parallel artificial membrane assay and human serum albumin. J Med Chem 51: 2009-2017.
61. Vogel HG Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. New York, NY: Springer, 2006.
62. Schuhmacher J, Kohlsdorfer C, Buhner K, Brandenburger T, Kruk R (2004) High-throughput determination of the free fraction of drugs strongly bound to plasma proteins. J Pharm Sci 93: 816-830.
63. Domenici E, Bertucci C, Salvadori P, Felix G, Cahagne I, Motellier S, Wainer IW (1990) Synthesis and chromatographic properties of an HPLC chiral stationary phase based upon human serum-albumin. Chromatographia 29: 170-176.
64. Bertucci C, Bartolini M, Gotti R, Andrisano V (2003) Drug affinity to immobilized target bio-polymers by high-performance liquid chromatography and capillary electrophoresis. J Chromatogr B 797: 111-129.
65. Xuan H, Hage DS (2005) Immobilization of alpha(1)-acid glycoprotein for chromatographic studies of drug-protein binding. Anal Biochem 346: 300-310.
66. Chen S, Sobansky MR, Hage DS (2010) Analysis of drug interactions with high-density lipoprotein by high-performance affinity chromatography. Anal Biochem 397: 107-114.
67. Soltes L (2004) The Hummel-Dreyer method: Impact in pharmacology. Biomed Chromatogr 18: 259-271.
68. Hage DS, Tweed SA (1997) Recent advances in chromatographic and electrophoretic methods for the study of drug-protein interactions. J Chromatogr B 699: 499-525.
69. Heegaard NHH, Kennedy RT (1999) Identification, quantitation and characterization of biomolecules by capillary electrophoretic analysis of binding interactions. Electrophoresis 20: 3122-3133.
70. Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: Implications for rational drug discovery. Biopharm Drug Dispos 23: 327-338.
71. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A (2007) On the rate and extent of drug delivery to the brain. Pharm Res 25 (8): 1737-1750.